---
document_datetime: 2026-01-13 11:03:47
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/blincyto-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: blincyto-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6521495
conversion_datetime: 2026-01-14 07:24:36.892684
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BLINCYTO

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                        |
|---------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000286935 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, | 27/11/2025                          |                                             | SmPC, Annex II and PL            | SmPC new text: Haemophagocytic lymphohistiocytosis (HLH)/Immune effector cell- associated haemophagocytic lymphohistiocytosis- |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.4, 4.8 of the SmPC in order to add a new warning on Haemophagocytic lymphohistiocytosis (HLH)/Immune effector-cell-associated haemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) following the evolving understanding of cytokine release syndrome and HLH/IEC-HS; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes to the PI in line also with the latest QRD revision of the PI.   |            |     | like syndrome (IEC-HS) have been observed in patients receiving BLINCYTO. HLH is a life- threatening syndrome characterized by fever, hyperferritinaemia, hepato- and/or splenomegaly, cytopenias, coagulopathy with hypofibrinogenaemia, haemophagocytosis and transaminitis. IEC-HS refers to the occurrence of HLH-like toxicities associated with immune effector cell therapies, characterized by excessive immune activation and dysregulated cytokine production leading to multisystem inflammation and organ dysfunction. HLH/IEC-HS should be considered when the presentation of CRS is atypical or prolonged. Patients should be monitored for clinical signs and symptoms of HLH/IEC-HS. For suspected HLH/IEC- HS, BLINCYTO must be interrupted for diagnostic workup, including evaluation for alternative causes of HLH such as infections, malignancies and autoimmune diseases. Prompt initiation of treatment for HLH/IEC-HS (e.g. corticosteroids, immunosuppressive or cytokine-directed therapy, and supportive care) should follow institutional or published guidelines. For more information, please   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000281362 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used                                                                                                                                                                                                                                                                                                                                                                 | 09/10/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                                       | in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted                                                                                                                            |            |             |                                                                                                                                                                                                                                                                     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000263899 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.4 of the SmPC to include information on a possible higher risk of seizures in patients with Down Syndrome who are receiving blinatumomab based on post marketing data and literature. The Package Leaflet is updated accordingly. The MAH also took the occasion to include some editorial changes in the PI. | 19/06/2025 | SmPC and PL | SmPC new text: Patients with Down syndrome may have a higher risk of seizures with BLINCYTO therapy; consider seizure prophylaxis prior to initiation of BLINCYTO for these patients. For more information, please refer to the Summary of Product Characteristics. |